Introduction {#S1}
============

The single-layer epithelium lining the gastrointestinal tract is exposed to a wide variety of substances, ranging from food and commensal microbes to enteric pathogens. In the steady-state the immune system underlying this epithelium samples the luminal contents to promote tolerance to dietary antigens^[@R1]--[@R3]^, a process that is central to maintaining immune homeostasis and health. However, during enteric infection, immune responses change to promote immunity and pathogen clearance. This shift in immune phenotype is not dictated solely by the nature of the antigens to which the immune system is responding, as evidenced by the induction of inflammatory responses to commensal gut flora during enteric infection^[@R4]^. Thus, exposure to innocuous luminal substances during enteric infection can lead to inappropriate inflammatory responses; however, these responses are not commonly observed. This indicates that mechanisms could exist to limit immune exposures to innoccous luminal antigens during infection. Moreover, pathogens might co-opt the pathways of steady-state immune sampling and use them as a portal to cross the epithelium, providing an additional impetus for the host to regulate steady-state antigen sampling processes during enteric infection. However, whether steady-state luminal antigen acquisition pathways are suppressed during enteric infection and the implications of these events on the course of enteric infection are largely unexplored.

Luminal substances can traverse the epithelium by several pathways including paracellular leak, epithelial barrier breach, transcytosis by M cells, passage through goblet cells (GCs), and direct capture by lamina propria (LP) dendritic cells (DCs)^[@R5]--[@R10]^. Of these, transfer via GCs, or goblet cell associated antigen passages (GAPs), represents a major pathway for steady-state luminal antigen transfer to the LP-DCs in a manner capable of inducing antigen specific T cell responses^[@R7]^. Moreover, GAP formation is a controlled process which can limit inappropriate exposure of the immune system to luminal substances^[@R11]--[@R13]^. In addition, enteric pathogenic bacteria can use GCs, and commensal bacteria can use inappropriately formed colonic GAPs, to cross the epithelium^[@R12]--[@R14]^. Together these observations suggest that inhibiting GAPs could limit antigen specific T cell responses to dietary antigens and pathogen translocation during infection, and therefore might represent a physiologic response to enteric infection. Accordingly, we investigated how GAPs and antigen specific T cell responses towards dietary antigen are altered during infection with *Salmonella enterica* subspecies I serovar Typhimurium.

Here we report that infection with *Salmonella* inhibits GAPs, a steady state luminal antigen acquisition pathway. Inhibition of GAPs during infection prevented inflammatory T cell responses to dietary antigen. In addition, we observed that translocation of *Salmonella* to the MLN required GCs and correlated with the presence of GAPs. Pretreatment with antibiotics has a well-described effect in abrogating colonization resistance by the gut microbiota and potentiating disease by allowing *Salmonella* to expand in the gut lumen^[@R15]--[@R21]^. Recently it has also been demonstrated that the dysbiosis induced by antibiotic pretreatment allows colonic GAP formation and translocation of commensal gut bacteria^[@R11]--[@R13]^. We also observed that manipulations overriding GAP suppression, including antibiotic pretreatment, facilitated the dissemination of *Salmonella*, worsened disease course, and reduced survival, independent overcoming colonization resistance of the gut microbiota. Thus inhibition of this steady state luminal antigen acquisition pathway during enteric infection serves to limit inappropriate antigen specific T cell responses to dietary antigens and to limit pathogen translocation. Moreover, we describe an unappreciated effect of antibiotics potentiating and worsening enteric infection that is distinct from overcoming colonization resistance of the gut microbiota.

Results {#S2}
=======

Salmonella inhibits small intestinal GAPs in a cell intrinsic manner {#S3}
--------------------------------------------------------------------

To evaluate if GAPs were inhibited during enteric infection, mice were given 5×10^8^ CFU wildtype or invasion-deficient (Δ*invG*) *Salmonella* into the small intestinal (SI) lumen, and SI GAPs density measured 1 hour later. Wildtype *Salmonella*, and to a lesser extent Δ*inv*G *Salmonella*, acutely suppressed SI GAP formation ([Fig. 1a and b](#F1){ref-type="fig"}). Further, we observed that SI GAPs were suppressed 1 day following oral gavage of 5×10^7^ CFU wildtype and xtent, Δ*invG Salmonella* ([Supplementary Fig. S1a](#SD1){ref-type="supplementary-material"}). GAP inhibition was even more prominent 2 and 3 days after infection ([Fig. 1b](#F1){ref-type="fig"} and [Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). While GC numbers decreased at day three of infection, the reduction in GAPs was more pronounced than the decrease in GCs ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}), and therefore the reduction in GAPs could not be explained by GC loss alone. Thus, *Salmonella* inhibits SI GAPs for days following infection.

GAP formation is induced by acetylcholine (ACh) acting on the muscarinic ACh receptor 4 (mAChR4) expressed by GCs^[@R11]^. Responsiveness to ACh by GCs to form GAPs is inhibited by activation of the epidermal growth factor receptor (EGFR) in GCs^[@R11]^. Inhibition of GAP formation can occur via activation of EGFR directly in GCs by luminal EGF or by GC intrinsic MyD88-dependent sensing of the luminal microbiota in colonic GCs, resulting in EGFR transactivation ^[@R11]^. However, GC intrinsic MyD88 dependent sensing of the microbiota does not suppress SI GAP formation^[@R11]^. We explored if these pathways previously identified to inhibit GAPs were required for GAP suppression during acute infection with *Salmonella*. Inhibition of EGFR activation (EGFRi) in the absence of infection did not increase SI GAPs ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}), consistent with prior observations that EGFR is not activated in SI GCs and not suppressing SI GAP formation in the steady state^[@R11]^. However, pharmacologic inhibition of EGFR activation 2 days after *Salmonella* infection partially reversed the suppression of SI GAPs ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). The inability to completely reverse GAP inhibition may be due to the short half-life of this pharmacologic inhibitor of EGFR activation^[@R22]^. Therefore we evaluated GAPs in mice where EGFR or Myd88, the upstream inducer of EGFR trans-activation, was deleted in GCs. Mouse atonal homologue 1 (Math1) is a transcription factor necessary for the development of neurons ^[@R23],[@R24]^ and secretory intestinal epithelial lineages including GCs, Paneth cells, and enteroendocrine cells^[@R25]^. Previous studies have demonstrated that mice with Cre recombinase inserted into the Math1 locus effectively targets intestinal GCs^[@R11],[@R24]^. We found that GC deletion of EGFR, or its upstream activator MyD88, using the inducible Math1 driven Cre recombinase^[@R11],[@R12],[@R24]^, completely reversed SI GAPs inhibition 1 hour after luminal administration of *Salmonella* as well as 2 days following oral infection, but did not increase SI GAPs in the absence of infection ([Fig. 1c and d](#F1){ref-type="fig"}). Thus, inhibition of SI GAPs during *Salmonella* infection occurs by activation of MyD88- and EGFR-dependent signaling pathways previously identified to inhibit colonic GAPs in the steady state^[@R11]^.

IL-1β inhibits GAPs during Salmonella infection {#S4}
-----------------------------------------------

Heat-killed cecal contents do not inhibit SI GAPs in the steady state, and deletion of MyD88 in GCs does not augment SI GAP density ([Fig. 1c](#F1){ref-type="fig"} and ^[@R11]^). This may be due to lower TLR expression and higher expression of inhibitors of TLR signaling by SI GCs when compared with colonic GCs^[@R11]^. These observations indicate that microbial products do not suppress SI GAPs via MyD88 signaling in GCs in the steady state. Similarly we observed that heat killed *Salmonella* did not inhibit SI GAPs ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}). However, GAP inhibition during *Salmonella* infection was dependent upon MyD88 ([Fig. 1c](#F1){ref-type="fig"}), suggesting that other stimuli may be activating MyD88 during infection. Further, we observed that SI GAP inhibition during *Salmonella* infection was associated with increased phosphorylation of EGFR in the epithelium, but did not correlate with increased levels of EGF ([Fig. 2a and b](#F2){ref-type="fig"}), prompting us to explore other MyD88-dependent pathways leading to EGFR activation. *Salmonella* infection induces IL-1β production by stromal cells^[@R26]^ and mononuclear phagocytes^[@R27]^, and IL-1β can signal via MyD88^[@R28]^, which activates the EGFR in GCs^[@R11]^. We found that IL-1β was significantly elevated in the epithelium 2 days following *Salmonella* infection. Wildtype *Salmonella* induced significantly more IL-1β than Δ*inv*G *Salmonella* ([Fig. 2c](#F2){ref-type="fig"}), correlating with increased GAP inhibition by wildtype *Salmonella* ([Fig. 1b](#F1){ref-type="fig"}). Moreover, administration of recombinant IL-1β systemically or into the gut lumen rapidly inhibited SI GAPs ([Fig. 2d](#F2){ref-type="fig"}), and inhibiting active IL-β release with the pan-caspase inhibitor Z-VAD-FMK reversed the inhibition of SI GAPs following *Salmonella* infection ([Fig. 2e](#F2){ref-type="fig"}). While this supports the involvement of IL-1β in GAP inhibition, Z-VAD-FMK may have effects beyond suppressing active IL-1β release. However, we observed that germline deletion of IL-1 receptor 1 (*Il1r1*^−/−^) did not alter SI GAP density in the steady state, but reversed SI GAP inhibition 2 days following oral *Salmonella* infection as well as 1 hour following luminal *Salmonella* administration ([Fig. 2f](#F2){ref-type="fig"}), thus confirming the necessity of this pathway for the suppression of SI GAPs during infection.

Suppression of SI GAPs during Salmonella infection limits responses to dietary antigen in draining MLN {#S5}
------------------------------------------------------------------------------------------------------

In the steady state, inhibition of GAPs or deletion of GCs/GAPs abrogates the ability of LP-DCs to acquire luminal antigen in a manner capable of inducing adaptive immune responses^[@R7],[@R11]^, a process that is critical for the induction of T cell responses in the draining MLN^[@R1],[@R2]^. This suggests that GAP inhibition during enteric infection would suppress antigen specific T cell responses to orally administered antigens. In addition, *Salmonella* infection can inhibit antigen presentation by DCs^[@R29]^ and/or kill DCs^[@R29],[@R30]^, further impairing generation of immune responses to dietary antigen. Conversely, *Salmonella* infection increases epithelial barrier permeability^[@R31]^ and induces LP-DC extension of trans-epithelial dendrites (TED) into the lumen^[@R9],[@R32]^, both of which might increase luminal antigen capture and antigen specific T cell responses to dietary antigens. To determine how *Salmonella* infection influences T cell responses to dietary antigen, uninfected and infected mice were injected i.v. with CFSE-labeled ovalbumin (Ova)-specific splenic T cells isolated from OT II T cell receptor transgenic mice, gavaged with Ova, and T cell proliferation in the MLN was quantified 48 hours later. *Salmonella*-infected mice had significantly suppressed antigen specificT cell proliferation to luminal Ova in the MLN ([Fig. 3a and b](#F3){ref-type="fig"}), despite equivalent abilities of OTII T cells to traffick to the MLN and despite having equivalent ability to respond to systemic Ova ([Supplementary Fig. 3a and b](#SD1){ref-type="supplementary-material"}). This suggests that the increased gut permeability and LP-DC TED extension during *Salmonella* infection do not translate into enhanced immune responses to luminal antigens and that the defect in antigen specific T cell proliferation in the MLN to luminal Ova is in part due to lack of antigen delivery to the MLN during infection. Further supporting this, we observed that inhibition of EGFR activation, which relieves GAP inhibition during *Salmonella* infection ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}), reversed the impairment of antigen specific T cell proliferation to dietary antigen during infection, but did not increase proliferation in the absence of infection ([Fig. 3a and b](#F3){ref-type="fig"}). Moreover, the impaired T cell proliferation to dietary antigen seen during infection was reversed by GC-specific deletion of MyD88 ([Fig. 3c and d](#F3){ref-type="fig"}), which relieves the suppression of GAPs during *Salmonella* infection ([Fig. 1c](#F1){ref-type="fig"}). A significant proportion of the OTII T cells in the MLN of uninfected Ova-gavaged mice expressed Foxp3, indicating differentiation into Tregs ([Fig. 3e and f](#F3){ref-type="fig"}). In contrast, *Salmonella* infection significantly reduced the population of OTII T cells expressing Foxp3 in the draining MLN after Ova gavage ([Fig. 3e and f](#F3){ref-type="fig"}). Notably, while GC-specific deletion of MyD88 restored antigen specific T cell proliferation to dietary Ova during *Salmonella* infection ([Fig. 3c](#F3){ref-type="fig"}), this did not restore Foxp3 expression ([Fig. 3e and f](#F3){ref-type="fig"}), but did induce an increase in the number of IL-17 producing OTII T cells responding to dietary Ova ([Fig. 3g and h](#F3){ref-type="fig"}). In light of studies demonstrating that inflammatory responses are generated toward commensal bacterial antigens during infection^[@R4]^, our findings suggest that one outcome of inhibiting GAPs during infection is to limit inflammatory antigen specific T cell responses to innocuous dietary substances in the gut lumen.

Salmonella uses GCs and GAPs as a portal of entry {#S6}
-------------------------------------------------

Animal models and *in vitro* studies have identified several strategies *Salmonella* can employ to cross the epithelial barrier, including barrier breach, transcytosis of M cells or other epithelial cells, direct capture by LP-DC extension of dendrites into the lumen, and paracellular penetration between epithelial cells^[@R10],[@R33]^. In addition to these pathways, the enteric pathogen *Listeria monocytogenes* has been found to selectively target GCs in order to cross the SI epithelial barrier^[@R14]^. Moreover, translocation of gut commensals across colonic epithelium requires GCs and is associated with the formation of colonic GAPs^[@R12]^. These observations prompted us to evaluate if *Salmonella* might use GCs and GAPs in the SI as a portal for entry. We observed that two hours following intraluminal inoculation, *Salmonella* preferentially localized with, and could be found within, SI GCs that had formed GAPs ([Fig. 4a](#F4){ref-type="fig"}). The SI and colonic lymphatics largely drain into distinct MLNs, and evaluation of the MLNs draining the SI and colon independently can inform where bacteria translocate across the epithelium in the gut^[@R12],[@R13],[@R34]^. Two days following oral infection, wildtype *Salmonella* was nearly absent from colon-draining MLN, but was easily found in SI-draining MLN ([Fig. 4b](#F4){ref-type="fig"}), indicating that wildtype *Salmonella* predominantly traversed the SI epithelium. Deletion of GCs abrogated dissemination of *Salmonella* to the SI-draining MLN, but did not affect colonization of Peyer's patches (PP) or spleen bacterial loads two days after infection ([Fig. 4b](#F4){ref-type="fig"}). This indicates that GCs are required for *Salmonella* to cross the SI epithelium to access the draining MLN early in infection, but are not required for infection of the PP or dissemination to the spleen. This also suggests that *Salmonella* dissemination to the spleen might be independent of traversing the non-follicle bearing epithelium in the SI, which has been indicated by others^[@R35]^.

Oral streptomycin treatment of mice prior to *Salmonella* infection potentiates colitis and is used to model the pathogenesis of human *Salmonella* enterocolitis^[@R17]^. Antibiotic pretreatment, disrupts the gut microbiota and allows *Salmonella* to more effectively colonize the lumen, increasing colonic inflammation and enhancing dissemination^[@R15]--[@R21]^. Moreover, antibiotic pretreatment allows Δ*inv*G *Salmonella* to traverse the epithelium and disseminate to MLN ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"} and ^[@R36],[@R37]^). We found that streptomycin pretreatment augmented bacterial dissemination specifically to the colon-draining MLN and augmented bacterial burden in the spleen, without altering bacterial burden in the SI-draining MLN or PP ([Fig. 4c](#F4){ref-type="fig"}). GAPs form spontaneously in the SI, but are suppressed in the colon due to GC-intrinsic microbial sensing, which inhibits GC responsiveness to ACh^[@R11]^; however, colonic GAPs are induced following treatment with some antibiotics and can facilitate translocation of commensal bacteria^[@R12],[@R13]^. We observed that deletion of GCs in streptomycin-pretreated mice abrogated both the ability of *Salmonella* to disseminate to the colon- and SI-draining MLNs and the increase in spleen titers ([Fig. 4d](#F4){ref-type="fig"}), indicating that GCs were required for *Salmonella* dissemination to the MLNs in the streptomycin pretreatment model.

In streptomycin-pretreated mice infected with wild-type *Salmonella*, the bacteria translocating to the colon draining MLN included both *Salmonella* and gut commensal bacteria, while those translocating to the SI draining MLN were *Salmonella* alone ([Supplementary Fig. 4b](#SD1){ref-type="supplementary-material"}). This is consistent with prior studies demonstrating that colonic GAPs, but not SI GAPs, facilitate the translocation of commensal bacteria^[@R12],[@R13]^ and indicates that these properties of SI and colonic GAPs to translocate bacteria do not change during infection. Pretreatment with kanamycin, which is also used in a *Salmonella* colitis model^[@R38],[@R39]^, similarly induced colonic GAPs and enhanced translocation to the colon-draining MLN and spleen, but not to the SI-draining MLN ([Supplementary Fig. 4c and d](#SD1){ref-type="supplementary-material"}). These observations suggest that during early phase of infection, GCs are required for translocation of *Salmonella* across the colonic epithelium in the streptomycin or kanamycin pretreatment models and that the enhanced pathogen burden in the spleen following streptomycin or kanamycin pretreatment is in part due to increased translocation across the colonic epithelium via GCs/GAPs.

Overriding GAP suppression worsens the course of Salmonella infection {#S7}
---------------------------------------------------------------------

Prior antibiotic use has been associated with an increased risk of *Salmonella* infection ^[@R40]--[@R42]^. A single, clinically relevant dose of many, but not all, antibiotics induces colonic GAPs and commensal bacterial translocation to the colon-draining MLN in mice. Therefore we evaluated the effects of pretreatment with lower doses of antibiotics that do (streptomycin and vancomycin) and do not (neomycin and tetracycline) induce GAPs^[@R12]^ on *Salmonella* infection. All antibiotic pretreatments significantly increased the luminal pathogen load when compared to mice not receiving antibiotics, with no significant differences in luminal *Salmonella* burden between the antibiotic treatment groups ([Fig. 5a](#F5){ref-type="fig"}). Pretreatment with antibiotics that induce colonic GAPs, but not pretreatment with those that do not induce colonic GAPs, significantly increased dissemination to the colon-draining MLN and reduced survival ([Fig. 5b and c](#F5){ref-type="fig"}). We observed that like spontaneously forming SI GAPs, colonic GAPs induced after antibiotic pretreatment were also inhibited two days after *Salmonella* infection ([Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}). Like SI GAPs, colonic GAPs induced following antibiotic administration were inhibited by IL-1β treatment in an EGFR-dependent manner ([Supplementary Fig. 5b and c](#SD1){ref-type="supplementary-material"}).

While the above observations suggest that antibiotic pretreatment enables more severe *Salmonella* infection, and this can be independent of overcoming colonization resistance of the gut microbiota, antibiotics may have a number of effects enhancing dissemination and worsening infection that are unrelated to their ability to induce colonic GAPs. Therefore, we evaluated the effect of deletion of MyD88 or EGFR in GCs to override the suppression of GAPs during *Salmonella* infection independent of manipulations of the gut microbiota by antibiotics. EGFR^fl/fl^Math1^Cre\*PR^ mice or MyD88^fl/fl^ Math1^Cre\*PR^ mice and their littermate controls were treated with RU486 prior to and during the first two days of infection to open GAPs in a pattern seen after a single dose of antibiotics^[@R12]^. Overriding the suppression of GAP formation via deletion of MyD88 or EGFR in GCs was sufficient to exacerbate *Salmonella* infection, as evidenced by increased production of inflammatory cytokines, increased colitis, and increased mortality when compared with littermate controls; indeed, mice lacking Myd88 or EGFR in GCs exhibited a disease course and survival similar to mice receiving streptomycin pretreatment ([Fig. 6a--e](#F6){ref-type="fig"}). Interestingly, bacterial burden in the colonic MLN was similar among EGFR^fl/fl^Math1^Cre\*PR^, MyD88^fl/fl^ Math1^Cre\*PR^, and streptomycin-pretreated wildtype mice ([Fig. 6e](#F6){ref-type="fig"}), despite the presence of a higher luminal pathogen burden in the streptomycin pretreatment group ([Fig. 6f](#F6){ref-type="fig"}). Together, these data suggest that antibiotics may exacerbate *Salmonella* infection by inducing colonic GAPs and allowing increased pathogen dissemination.

Discussion {#S8}
==========

The intestinal epithelium is a major interface between the host and the environment, which includes food, the commensal microbiota, and potential pathogens. The delivery of luminal antigens across the intestinal epithelium in a manner capable of inducing adaptive immunity is a critical and early step in intestinal immune responses to luminal substances. In the steady state, these responses are characterized by the induction of Tregs enforcing tolerance to dietary and commensal antigens^[@R43]--[@R45]^. However, during infection the tone of the immune response changes to promote pathogen clearance and protective immunity. Inflammatory T cell responses can be induced to luminal non-pathogens encountered in the setting of enteric infection^[@R4]^. These inflammatory T cell responses can be long-lived, and therefore limiting the immune system's exposure to non-pathogenic antigens during infection would reduce the opportunity for developing inappropriate inflammatory responses. Here, we explored how an enteric infection alters the delivery of luminal antigens to immune system early in the course of infection. We focused our studies on GCs and GAPs, as the formation of GAPs is tightly controlled, and GAPs are a major pathway delivering antigens to the LP immune system in a manner capable of inducing adaptive immunity^[@R7],[@R11]^. Thus, the regulation of GAP formation is a potential mechanism limiting exposure to luminal substances during infection ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}).

In the steady state, GAPs form continuously in the SI due to GC responsiveness to ACh ^[@R7],[@R11]^. However, GC responsiveness to ACh is repressed in the colon, as MyD88-dependent sensing of the microbiota activates EGFR in GCs suppresses responses to ACh^[@R11]^. Microbial sensing via MyD88 does not suppress SI GAP formation despite similar levels of expression of MyD88 in SI and colon GCs; however, the ability of EGFR activation to inhibit GAP formation in GCs is retained in the SI^[@R11]^. This distinction may be related to lower expression of TLRs and higher expression of suppressors of TLR signaling in SI GCs when compared with colonic GCs^[@R11]^, or other yet to be identified factors. In the present work, we show that infection with wildtype *Salmonella* acutely inhibited GAPs, and this inhibition was dependent upon MyD88 and EGFR in GCs. Like the TLR signaling pathway, IL-1 receptor signaling relies on MyD88^[@R28]^. Infection with *Salmonella* rapidly induces IL-1β release by stromal cells^[@R26]^ and in intestinal phagocytes via activation of NLRC4-inflammasomes^[@R46]^. NLRC4 activation and IL-1β release by intestinal phagocytes during enteric infection is dependent upon an intact type III secretion system^[@R46],[@R47]^, which is disrupted in Δ*invG Salmonella*^[@R48]--[@R50]^, providing an explanation for the higher efficiency of wildtype *Salmonella* at MyD88-dependent GAP inhibition than the Δ*invG* mutant. Indeed, we found that IL-1β was significantly elevated following *Salmonella* infection and correlated with the ability of wildtype *Salmonella* to more effectively inhibit GAPs when compared with Δi*nvG Salmonella*, that recombinant IL-1β could rapidly inhibit GAPs, and that *Salmonella* failed to inhibit GAPs in IL-1 receptor-deficient mice.

We observed that *Salmonella* infection inhibited dietary antigen-specific T cell proliferation and Foxp3 induction. Interestingly, *Salmonella* has been reported to induce increased permeability of the intestinal barrier^[@R31]^ and to promote the extension of TEDs by LP-DCs ^[@R9],[@R32]^. Despite these reported effects, we observed that *Salmonella* inhibition of GAPs correlated with reduced immune response to dietary antigen during infection. Processes other than GAP inhibition can limit antigen specific T cell proliferation to luminal substances during infection. When DCs are infected with *Salmonella*, presentation of peptides on MHCII and the ability to stimulate antigen-specific T cell proliferation is reduced^[@R29]^. Further, *Salmonella* has been reported to kill DCs^[@R30]^, which would limit their ability to induce antigen-specific T cell proliferation towards luminal substances. While this may be occurring in our studies, we do not believe it explains the observed reduction in T cell proliferation to luminal antigens in the draining MLN. Overriding GAP suppression by wildtype *Salmonella,* by deleting MyD88 in GCs, or by pharmacologically inhibiting EGFR signaling, relieved the inhibition of T cell proliferation to luminal antigen in the MLN. These maneuvers targeting GCs do not reduce the pathogen burden and, due to the ability of invasive *Salmonella* to use GAPs as a portal of entry, may instead increase the pathogen burden, while simultaneously increasing T cell proliferation in response to luminal antigen in the MLN. These data are inconsistent with reduced antigen presentation by infected DCs or killing of DCs by *Salmonella* as the only events suppressing T cell proliferation to luminal antigen during infection.

In the steady state, tolerance to dietary antigen occur in the SI and are characterized by the induction of tolerogenic Foxp3^+^ Tregs^[@R1],[@R3],[@R51]^. In accordance with this, we observed substantial induction of Foxp3^+^ Ova-specific T cells in the MLN of uninfected mice receiving dietary Ova. In line with our observations of reduced tolerance to dietary antigen during infection, we found that induction of Ova specific Foxp3+ T cells was reduced during *Salmonella* infection. However, deletion of MyD88 to relieve inhibition of GAPs during infection did not restore Treg induction, despite restoring antigen specific T cell proliferation to dietary Ova, and in fact induced more IL-17 producing Ova specific T cells in the MLN. Thus similar to T cell responses to commensal bacterial antigens^[@R4]^, inflammatory responses are also generated in response to dietary antigens encountered during infection.

We found that wildtype *Salmonella* uses GCs/GAPs to cross the SI epithelium and gain access to the draining MLN. This was the predominant pathway delivering *Salmonella* to the MLN early in infection, as evidenced by the near absence of *Salmonella* in the MLN following deletion of GCs. Moreover, we found that overriding the suppression of GAPs during *Salmonella* infection increased the pathogen burden in the MLN indicating that inhibition of GAPs may be a mechanism limiting pathogen dissemination. While it appears paradoxical that *Salmonella* would both inhibit GAPs and use them as a route of entry, we believe the pathogens found in the MLN are early invaders some of which induce IL-1β release by LP mononuclear phagocytes subsequently inhibiting GAPs and limiting further dissemination. One limitation of our studies is that they were largely focused on early time points in infection, raising the possibility that other routes of entry may contribute to dissementation to the MLN at later time points. While it is possible that GAP inhibition during infection, diminishes the host's immune response to Salmonella, we observed that overriding GAP inhibition resulted in worsened disease, indicating that GAP inhibition during infection overall is favorable to the host and a physiologic response during infection. Potentially consistent with our findings, *IL1r1*^−/−^ mice are more susceptible to orogastric infection, but not peritoneal infection by *Salmonella*^[@R27]^, suggesting that loss of GAP inhibition by IL-1β and enhanced dissemination may contribute to this differential susceptibility to these routes of *Salmonella* infection.

Prior antibiotic use has been associated with an increased risk for infection by *Salmonella* in humans^[@R40]--[@R42]^. The effect of antibiotics to increase the risk of, and potentiate, enteric infection may be due to a reduction of the mucus layer or alterations in the environment, supporting pathogen residence and growth^[@R15],[@R20],[@R52]^. Indeed, elegant studies have demonstrated that disruption of the microbiota by antibiotics not only creates a space for *Salmonella* to colonize but also alters the nutrient environment to favor growth of *Salmonella*^[@R15],[@R20]^. Our observations indicate that the effect of antibiotics also extends to promoting *Salmonella's* translocation across the colonic epithelium and dissemination. We observed a similarly increased disease severity in streptomycin-pretreated mice and in mice with cell type-specific deletion of components of the pathways normally suppressing GAP formation. This indicates that facilitating *Salmonella* translocation and dissemination, without disrupting the gut microbiota and increasing luminal pathogen load via antibiotic administration, was sufficient to potentiate disease. Further, these effects were seen with antibiotics that do, but not with antibiotics that do not, induce colonic GAPs, despite similar burdens of luminal *Salmonella*. Importantly, these observations may inform the design of therapeutic antimicrobial regimens to target enteric pathogens without facilitating their translocation.

In total, we demonstrate how the delivery of luminal substances to the intestinal immune system is altered early in the course of infection and how a steady state antigen delivery pathway is used by an enteric pathogen as a portal of entry. We acknowledge that these studies were performed in an *in vivo* infection model and accordingly are complex and open to other interpretations regarding the events controlling antigen-specific T cell responses to dietary antigen and pathogen dissemination. However, combined with previous work demonstrating a role for GAPs in luminal antigen delivery and bacterial translocation, these findings indicate a critical role for GAP regulation limiting T cell responses to luminal antigens and pathogen dissemination during infection. Beyond this, we uncovered an unappreciated link between precedent antibiotic therapy and increased risk for enteric infection that is independent of the role of antibiotics overcoming colonization resistance of the gut microbiota ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}). These observations provide a conceptual framework to better understand how controlled access to luminal antigens is integrated to promote appropriate mucosal immune responses in the steady state and during enteric infection.

Materials and Methods {#S9}
=====================

Mice {#S10}
----

Mice used in this study were on the C57BL/6 background and bred in house. Where possible, cohoused littermates were used as experimental controls. C57BL/6 mice, *IL1r1*^−/−^ mice^[@R53]^, Myd88^fl/fl^ mice^[@R54]^, Math1^Cre\*PR^ mice^[@R24]^, Math1^fl/fl^ mice^[@R25]^, OTII T cell receptor transgenic mice^[@R55]^, congenic CD45.1 B6/SJL mice, and Foxp3^GFP^ mice^[@R56]^ were initially purchased from The Jackson Laboratory (Bar Harbor, ME). CD45.1 B6/SJL mice, Foxp3^GFP^ mice, and OTII mice were crossed to generate CD45.1 Foxp3^GFP^ OTII mice for adoptive transfer of Ova specific T cells. Mice with a Cre recombinase inserted into the mouse atonal homologue 1 (Math1) locus, Math1^Cre\*PR^ mice, can effectively delete floxed genes or label secretory epithelial lineages, including GCs, Paneth cells, and enteroendocrine cells^[@R11]^. Transgenic mice in which a tamoxifen-dependent Cre recombinase is expressed under the control of the villin promoter (vil-Cre-ER^T2^)^[@R57]^ mice were a gift from Sylvie Robine (Institut Curie, Paris, France). Math1^fl/fl^vil-Cre-ER^T2^ mice and the injection protocol to induce GC deletion were previously described ^[@R11]^. EGFR^fl/fl^ mice^[@R58]^ were a gift from Dr. David Threadgill, University of North Carolina. EGFR^fl/fl^ mice and Myd88^fl/fl^ mice were bred to Math1^Cre\*PR^ mice^[@R24]^ to generate mice with an inducible deletion of EGFR in GCs. To induce deletion of EGFR or MyD88, EGFR^fl/fl^Math1^Cre\*PR^ mice or MyD88^fl/fl^ Math1^Cre\*PR^ mice were treated with 200μg RU486 (mifepristone, Caymen Chemicals, Ann Arbor, MI) dissolved in sesame oil (Acros Organics, Sigma-Aldrich) daily. All mice received regular chow diet and autoclaved water. Animal procedures and protocols were performed with approval of the Institutional Animal Care and Use Committee at Washington University School of Medicine.

Bacteria strains/infection {#S11}
--------------------------

*Salmonella typhimurium* wildtype strain SB300A1^[@R59]^, its isogenic mutant *ΔinvG*, and *S. typhimurium* strain χ3761^[@R60]^, transformed with a lethal balanced GFP expression plasmid to create *Salmonella*-GFP (unpublished strain created by Xin Zhang in the Miller lab) were grown with shaking overnight at 37°C in Luria-Bertani (LB) broth, subcultured for 4 h, and washed twice with cold PBS prior to use.

Intra-luminal infection was performed by innoculating 5×10^8^ CFU of bacteria into the SI lumen of anesthetized mice. For oral *Salmonella* infections, mice were deprived of food for 4 h and gavaged orally with 5×10^7^ CFU of bacteria in 200 μlPBS. Mice were kept without food and water for 1 h after infection. The final infection dose was verified by plating serial dilutions of the bacterial suspension on LB agar plates. In some experiments, mice were treated with 7.5 mg of streptomycin^[@R61]^, or 10mg kanamycin^[@R38],[@R39]^ in 100 μl of PBS. To compare the effect of clinically relevant doses of different antibiotics, mice were gavaged with 500 μg neomycin, 500 μg tetracycline, 500μg streptomycin, or 250μg vancomycin 24hr prior to infection. EGFR^fl/fl^Math1^Cre\*PR^ mice and MyD88^fl/fl^ Math1^Cre\*PR^ mice were treated with RU486 5 days and 2 days prior to infection to open colonic GAPs in a pattern similar to that seen after a single dose of antibiotics^[@R12]^.

Organ Isolation and homogenization {#S12}
----------------------------------

MLN, spleen, and PP were retrieved and placed in gentamicin solution for 15 min. The gentamicin was washed away with cold PBS prior to grinding. All tissues were placed in 500 μl PBS and homogenized with a PowerGen 125 tissue homogenizer (Fisher Scientific). Live bacterial burden was determined by plating LB agar. Individual bacterial species were identified using matrix-assisted laser desorption ionization-time of flight mass spectrometry (Biotyper, Bruker Corporation, CA), as described previously^[@R12]^.

Enumeration of GAPs and GCs {#S13}
---------------------------

SI and colonic GAPs were enumerated on fixed tissue sections as previously described^[@R7],[@R11]^. Briefly, tetramethylrhodamine-labeled 10 kD dextran was administered in the jejunum and proximal colon of anesthetized mice. After 1 hour, mice were sacrificed and tissues thoroughly washed with cold PBS before fixing in 10% formalin buffered solution. Tissues were embedded in optimal cutting temperature compound (Fisher Scientific, Pittsburgh, PA); 7-μm sections were prepared, stained with 4′,6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich) and imaged using an Axioskop 2 microscope (Carl Zeiss Microscopy, Thornwood, NY). GAPs were identified as dextran-filled columns measuring approximately 20 μm (height) × 5 μm (diameter) traversing the epithelium and containing a nucleus, and were enumerated as GAPs/villus cross section in the SI or GAPs/crypt cross section in the colon. Fixed SI tissue sections were stained with periodic acid-Schiff (PAS; Sigma-Aldrich) according to manufacturer's instructions, and images were acquired on the Axioskop 2. In some experiments, mice were treated with 500 μg/kg tryphostin AG1478 (inhibitor of EGFR phosphorylation; Sigma-Aldrich) i.p. 30 min prior to luminal dextran administration.

IL-1β and caspase inhibitor administration {#S14}
------------------------------------------

Mice were treated intraperitoneally or luminally with 100 ng recombinant IL-1β (R&D Systems) 1 hour prior to intraluminal dextran administration. To study the effect of IL-1β signaling blockade, mice were administered intraperitoneally with 10 mg/kg of pan-caspase inhibitor Z-VAD-FMK (R&D Systems) 1 hour prior to intraluminal dextran administration.

Enzyme-linked immunosorbent assays {#S15}
----------------------------------

Serum levels of IL-6 and IFN-γ were measured using Mouse IL-6 and IFN-γ ELISA kit (eBioscience), according to manufacturer's protocol. To measure the concentration of EGF (R&D Systems), phosphorylated-EGFR (R&D Systems) or IL-1β (eBioscience) in the SI-epithelium, a 5-cm portion of jejunum was opened longitudinally and washed with PBS. The epithelial cell layer was scraped from the submucosa with a glass slide, and cells were homogenized in 1 mL PBS. Cells were centrifuged, and supernatant was collected and ELISA performed per the manufacturer's protocol.

Adoptive T cell transfer {#S16}
------------------------

To evaluate the effects of *Salmonella* infection on T cell trafficking and antigen specific T cell proliferation, single cell suspensions of Ova-specific T cells were prepared from spleens and MLNs of CD45.1^+^ OTII T cell receptor transgenic mice, and CD4 T cell enrichment was performed using magnetic beads (Stemcell Technology \#19752, Vancouver, BC). Enriched CD4^+^ T cells were labeled with 2 μM CFSE (Invitrogen). 2×10^6^ CFSE-labeled cells were adoptively transferred *i.v*. into sex matched recipient mice 1 day after mock infection or infection with *Salmonella.* Twenty-four hours after transfer, mice were orally gavaged with 20 mg ovalbumin (Sigma) or in some experiments given 200μg of i.v. ovalbumin, and after 2 days later MLNs were removed and single-cell suspensions were prepared and analyzed by flow cytometry for CD45.1, CD3, Vβ5, Vα2 and CSFE. In experiments evaluating the trafficking of adoptively transferred T cells, mice were not gavaged with Ova, and transferred T cells evaluated on the same schedule.

To evaluate the phenotype of transferred cells, single cell suspensions from spleen and MLNs from Ova-specific CD45.1^+^ Foxp3^GFP^ OTII T cell receptor transgenic mice were flow cytometrically sorted for GFP^−^, Vβ5^+^, Vα2^+^, CD45.1^+^, CD62^hi^ cells. 5×10^5^ cells were intravenously administered into recipient (CD45.2) mice one day after infection. One day later, mice were gavaged with 20mg OVA, 3 days later single cell suspensions were isolated from the MLN, and evaluated for Foxp3 expression or were stimulated for 3 hour with 10 ng/ml PMA, 500 ng/ml inomycin (both Sigma-Aldrich) and 2μM Brefeldin A (eBioscience) to evaluate cytokine expression by intracellular flow cytometry. Samples were acquired on a FACScan cytometer (BD Bioscience, San Jose, CA), and data analysis was performed using FlowJo software (TreeStar, Inc.).

Bacterial DNA isolation and quantification of *Salmonella* in intestinal contents {#S17}
---------------------------------------------------------------------------------

Entire SI and colonic contents were collected, placed in 1 mL lysis buffer and 200 mg 0.1mm diameter zirconia silica beads (BioSpec, Bartlesville, OK) and vortexed on a bead beater (FastPrep 24, MP Biomedicals). DNA isolation was performed using DNA/RNA Extraction kit (Qiagen, Valencia, CA). Quantification of *Salmonella* was performed by real-time PCR using primers specific to *siiA* (ACGACTGGGATATGAACGGGGAA and TCGTTGTACTTGATGCTGCGGAG)^[@R62]^ and measured against a standard curve.

Histopathologic evaluation {#S18}
--------------------------

On day 5 of *Salmonella* infection, colonic tissue was fixed in formalin and washed in ethanol before embedding. Hematoxylin and eosin staining was performed, and pathology was scored as previously described^[@R12]^. In brief, edema (0--3 points), lymphocyte infiltration (0--3 points), epithelial damage (0--3 points) were evaluated, and a total score between 0 and 9 points was obtained.

Statistical analysis {#S19}
--------------------

Data analysis was performed using GraphPad Prism (GraphPad Software Inc., San Diego, CA). Statistical significance was defined as p\<0.05.
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![Goblet cell-associated antigen passage (GAP) formation is inhibited by Salmonella in a MyD88 and EGFR dependent manner\
(a) Fluorescent images of SI villus cross section of C57BL/6 mice given luminal 10kD dextran (red) and DAPI (blue), one hour after receiving luminal PBS (left), 5×10^8^ CFU invasion deficient *Salmonella* (Δ*invG Sal*; center) or 5×10^8^ CFU wildtype *Salmonella* (WT-*Sal*; right). (b) Density of GAPs in C57BL/6 mice, given 5×10^8^ CFU or wildtype or Δ*invG Salmonella* in the SI lumen 1 hr earlier (left panel) or given 5×10^7^ CFU wildtype or Δ*invG Salmonella* orally 2 days earlier (right panel). (c) MyD88^fl/fl^ Math1^Cre\*PR^ and (d) EGFR^f/f^ Math1^Cre\*PR^ mice and littermate controls were treated with RU486 to delete MyD88 or EGFR from GCs and were administered with 5×10^8^ CFU of wildtype *Salmonella* or PBS for 1 hour within the SI-lumen (left panel), or gavaged with 5×10^7^ CFU wildtype *Salmonella* and SI tissue sections were evaluated 2 days later (right panel). Graphs depict the density of GAPs in SI villus cross section of uninfected and infected mice. Data represented as the mean ± SEM. Scale bar in a= 50 μm. \*p\<0.05, ns = not significant. n=5 or more mice with 60 or more villus cross sections per mouse examined for each condition.](nihms935989f1){#F1}

![IL-1β inhibits SI GAPs during Salmonella infection\
(a--c) Enzyme-linked immunosorbent assays for a) phospho-EGFR, b) EGF, and c) IL-1β on SI epithelium from uninfected C57BL/6 mice or C57BL/6 mice infected with 5×10^7^ CFU Δ*inv*G or wildtype *Salmonella* 2 days earlier. (d) Density of GAPs in C57BL/6 mice one hour after i.p. injection or luminal injection of vehicle or 100 ng recombinant IL-1β. e) Density of SI GAPs in C57BL/6 mice 2 days after oral PBS or 5×10^7^ wildtype *Salmonella* and daily injection with vehicle or 10 μg/kg of pan-caspase inhibitor (Z-VAD-FMK). (f) Density of GAPs in C57BL/6 or *IL1r*^−/−^ mice, given 5×10^8^ CFU of wildtype *Salmonella* in the SI lumen 1 hr earlier (left panel) or given 5×10^7^ CFU wildtype *Salmonella* orally 2 days earlier. Data presented as the mean ± SEM, \*p\<0.05, ns-not significant. n=5 or more mice with 60 or more villi cross sections evaluated for each condition.](nihms935989f2){#F2}

![Inhibition of GAP formation by Salmonella impairs antigen specific T cell proliferation and Treg induction to dietary antigen in the draining MLN\
(a) Histograms and (b) quantification of proliferation of adoptively transferred CSFE labeled Ova specific CD4+ OTII T cells in the MLN of C57BL/6 mice that were uninfected or infected with 5×10^7^ CFU *Salmonella* and gavaged with Ova. (c) Flow cytometry plots and d) quantification of proliferation of adoptively transferred CSFE labeled Ova specific CD4+ OTII T cells in the MLN of mice lacking MyD88 in GCs or their littermate controls that were uninfected or infected with 5×10^7^ CFU *Salmonella* and gavaged with Ova. (e and g) Flow cytometry plots and (f and h) quantification of Foxp3 and IL-17 expression by adoptively transferred Ova specific CD4+ OTII T cells in the MLN of mice lacking MyD88 in GCs or littermate controls that were uninfected or infected with 5×10^7^ CFU *Salmonella* and gavaged with Ova. Data are pooled from two independent experiments, each with 6--8 mice per group. \*p\<0.05, ns = not significant. Data presented as the mean ± SEM.](nihms935989f3){#F3}

![Dissemination of Salmonella to draining MLNs requires GCs\
a) Fluorescent images of a SI villus cross section (left) and a confocal image of a SI GAP (right) in C57BL/6 mice 2 h after receiving luminal 10kDa dextran (red) and GFP-expressing *Salmonella* (green); nuclear stain DAPI (blue) in right panel. Colony forming units (CFUs) in the colon-draining MLN (C-MLN), SI-draining MLN (S-MLN), Peyer's patches (PP), and spleen (SPL) 2 days after infection with 5×10^7^ CFU wildtype *Salmonella* in b) goblet cell-deficient (Math1^f/f^ ERT2^Cre^) mice or littermate control (Math1^f/f^) mice, c) untreated or streptomycin pretreated C57BL/6 mice or c) goblet cell-deficient mice littermate controls pretreated with streptomycin. Data are pooled from 3 independent experiments, each with 5 mice per group. \*p\<0.05, ns = not significant, scale bar = 50μm, data are presented as mean ± SEM.](nihms935989f4){#F4}

![Pretreatment with oral antibiotics that induce colonic GAPs, but not with those that do not induce colonic GAPs, increases Salmonella dissemination and reduces survival\
a) *Salmonella* in the colon contents and b) CFUs in the colon draining MLN and c) Kaplan-Meier survival curves in untreated C57BL/6 mice or C57BL/6 mice pretreated with neomycin (500 μg), tetracycline (500 μg), streptomycin (500 μg), or vancomycin (250 μg) 1 day prior to infection with 5×10^7^ CFU *Salmonella*. Data represented as the mean ± SEM, \*p\<0.05, ns-not significant. n=5 or more mice.](nihms935989f5){#F5}

![Overriding GAP inhibition results in increased dissemination, worsened colitis, and reduced survival independent of alterations in luminal Salmonella burden\
a) Representative hematoxylin and eosin-stained colon sections, b) Kaplan-Meier survival curves, c) histological scores, d) serum cytokine concentrations e) CFUs in colon-draining MLNs, and f) luminal *Salmonella* burden in untreated C57BL/6 mice, streptomycin-pretreated C57BL/6 mice, mice lacking EGFR in GCs (EGFR^ff^Math1^PR\*Cre^), mice lacking MyD88 in GCs (MyD88^ff^Math1^P\*RCre^), and floxed littermate controls infected with 5×10^7^ CFU of *Salmonella*. Mice in panels a and c--f were analyzed 6 days following infection. n=5 or more mice, \*=p\<0.05, data is presented ± SEM Scale bar = 100μm.](nihms935989f6){#F6}
